<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089647</url>
  </required_header>
  <id_info>
    <org_study_id>Adult OSA drug study</org_study_id>
    <secondary_id>IISP 37206</secondary_id>
    <nct_id>NCT01089647</nct_id>
  </id_info>
  <brief_title>Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA)</brief_title>
  <official_title>Montelukast and Nasa ICS for Treatment of Mild Obstructive Sleep Apnea in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Romaker &amp; Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Romaker &amp; Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In children with mild apnea combined therapy with an inhaled nasal steroid and a medication
      that decreased nasal congestion (montelukast) was shown to be effective. We are testing to
      see if this combination works in adults with mild apnea as well.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 adults with mild OSA (&lt; 5 apneas/hypopneas per hour of sleep) will receive either a
      combination of two medicines that decrease nasal congestion-montelukast and nasal
      budesonide-or a placebo pill and nasal spray. After 3 months of therapy, a repeat sleep study
      will be done to determine the differences, if any, in the frequency of sleep disordered
      breathing in the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decrease the number of apnea/hypopnea to &lt;5 per hour of sleep</measure>
    <time_frame>3 months</time_frame>
    <description>by decreasing nasal congestion, we hope to decrease the number of respiratory events per hour of sleep back to the normal range</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>budesonide nasal spray and a montelukast pill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill, salt water nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide nasal spray and a montelukast pill</intervention_name>
    <description>budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks</description>
    <arm_group_label>budesonide nasal spray and a montelukast pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo: sugar pill and salt water nasal spray</intervention_name>
    <description>sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks</description>
    <arm_group_label>sugar pill, salt water nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 - 100 years

          -  RDI between 5 - 15

          -  all races

          -  both sexes

        Exclusion Criteria:

          -  craniofacial, syndromic, neurological abnormalities

          -  current or previous use of Singular, Rhinocort within last 6 months

          -  acute upper respiratory infections

          -  recent nasal trauma, nasal surgery, nasal septum perforation

          -  known immunodeficiency or under going immunosuppressant therapy

          -  current therapy with drugs that interact with Montelukast or Budesonide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Romaker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Romaker &amp; Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Romaker &amp; Associates</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Romaker &amp; Assoc</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Romaker &amp; Associates</investigator_affiliation>
    <investigator_full_name>Ann M. Romaker, MD</investigator_full_name>
    <investigator_title>UMKC sleep fellowship program director</investigator_title>
  </responsible_party>
  <keyword>OSA</keyword>
  <keyword>Medical treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

